Beecher, G., Anderson, D., Siddiqi, Z. A. September 3, 2017

Objective:

To investigate the efficacy, tolerability, and safety of subcutaneous immunoglobulin (SCIg) in patients with mild to moderate myasthenia gravis (MG) exacerbation.

Methods:

We performed a prospective, open-label, phase 3 trial in patients with MG aged 18 years or older and mild to moderate worsening (transition from Myasthenia Gravis Foundation of America class I to II/III or class II to III), treated with SCIg (2 g/kg), self-administered over 4 weeks.… Read More...

Cho, H., Baek, M. S., Choi, J. Y., Lee, S. H., Kim, J. S., Ryu, Y. H., Lee, M. S., Lyoo, C. H. September 3, 2017

Objective:

To investigate tau distribution in patients with corticobasal syndrome (CBS) using 18F-AV-1451 PET.

Methods:

Six consecutively recruited patients with CBS and 20 age-matched healthy controls underwent 2 PET scans with 18F-AV-1451 (for tau) and 18F-florbetaben (for β-amyloid).… Read More...

De Meo, E., Moiola, L., Ghezzi, A., Veggiotti, P., Capra, R., Amato, M. P., Pagani, E., Fiorino, A., Pippolo, L., Pera, M. C., Comi, G., Falini, A., Filippi, M., Rocca, M. A. September 3, 2017

Objective:

To explore the structural and functional integrity of the sustained attention system in patients with pediatric multiple sclerosis (MS) and its effect on cognitive impairment.

Methods:

We enrolled 57 patients with pediatric MS and 14 age- and sex-matched healthy controls (HCs).… Read More...

Suzuki, S., Ishikawa, N., Konoeda, F., Seki, N., Fukushima, S., Takahashi, K., Uhara, H., Hasegawa, Y., Inomata, S., Otani, Y., Yokota, K., Hirose, T., Tanaka, R., Suzuki, N., Matsui, M. September 3, 2017

Objective:

To report the clinical features of myasthenia gravis (MG) induced by treatment with immune checkpoint inhibitors using 2-year safety databases based on postmarketing surveys in Japan.

Methods:

We studied 10,277 patients with cancer who had received monotherapy with either nivolumab or ipilimumab between September 2014 and August 2016.… Read More...

Li, G., Mayer, C. L., Morelli, D., Millard, S. P., Raskind, W. H., Petrie, E. C., Cherrier, M., Fagan, A. M., Raskind, M. A., Peskind, E. R. September 3, 2017

Objective:

To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure.

Methods:

Participants were 45–64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol.… Read More...

Kim, H. J., Evoli, A. September 3, 2017

Cancer and autoimmunity can be viewed as differing consequences of deranged immune responses. The overexpression of certain molecules could result in development of cancer (failure of the immune system to control tumor cell growth), whereas oversuppression of the same molecules could lead to autoimmunity (failure of the immune system to regulate autoreactive responses).… Read More...

Andoird App
Loading...